- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00782496
Glucose Meter Study
January 29, 2016 updated by: Ascensia Diabetes Care
A New Contour Blood Glucose Monitoring System With High Frequency Testing Patients
The purpose of this study is to evaluate if the meal marker and reminder feature of the Contour meter along with education maintains or increases frequency of testing blood sugar after meals and enables behavioral changes that may lead to improvement in glycemic control.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
211
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Atlanta Diabetes Associates
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55416
- International Diabetes Center
-
-
New York
-
New York City, New York, United States, 10029
- Mount Sinai School of Medicine
-
-
Washington
-
Seattle, Washington, United States, 98105
- University of Washington Medical Center/Diabetes Care Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Persons with type 1 or type 2 diabetes
- Persons who are on a pump or are taking at least 1 mealtime injection of insulin a day
- Persons at least 21 years of age
Persons willing to complete all study visits and study procedures including:
- Using the meal-marker + reminder feature regularly (Group 2 subjects only)
- Using the paper logbook provided (both Groups)
- Testing their BG at least 3 times a day during the entire study.
- Persons who are able to speak, read and understand English
- Persons who are currently performing self-testing of blood glucose at home routinely (at least 3 times per day) for 4 weeks or more
Exclusion Criteria:
- Persons who have been using a CONTOUR, BREEZE or BREEZE 2 meter regularly during the previous 6 months
- Persons who test over 6 times/day regularly
- Persons who wear a BG sensor 2 weeks or more during each month.
- Persons with home heath aides who assist with their BG testing.
Persons with the following impairments which, in the opinion of the investigator, would seriously compromise the integrity of the study:
- Significant visual impairment
- Significant hearing impairment
- Cognitive disorder
- Significant unstable co-morbidity (with notable change within the past 3 months)
- Any other condition as per investigator's discretion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Level1 Basic Meter Features
Adults with type 1 and type 2 diabetes use only basic features (Level 1) to test their blood.
The CONTOUR meter has the basic features such as small meter size, easy to use , No Coding™ technology, 5-second test time, small sample size (0.6 µL), automatic control solution marking, 480 reading memory capacity.
|
Diabetes education and a new meter with basic features
|
|
Experimental: Level 2 Advanced Meter Features
Adults with type 1 and type 2 diabetes additionally access and use more advanced meter features(Level 2)during blood glucose testing.
The advanced features include ability to mark blood glucose values as obtained before or after meals or to set an audible reminder to test.
|
Diabetes education and a new meter with advanced features
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Average Number of Weekly Post-Prandial Blood Glucose Tests Performed by Subjects Using Either Basic or Advanced Meter Features
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Level 2 Participants Who Rated Helpfulness of Advanced Meter Features as 1 or 2
Time Frame: Over six month period
|
Level 2 participants, who used advanced meter features, responded to questionnaires.
They rated helpfulness of the meal marker reminder feature on a 5 point scale, 1 being strongly agree and 5 being strongly disagree.
|
Over six month period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard M Bergenstal, MD, International Diabetes Center At Park Nicollet
- Principal Investigator: Dace Trence, MD, University of Washington Medical Center/Diabetes Care Center
- Principal Investigator: Bruce W Bode, MD, Atlanta Diabetes Associates
- Principal Investigator: Ronald Tamler, MD, Phd, MBA, Icahn School of Medicine at Mount Sinai
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2008
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
October 28, 2008
First Submitted That Met QC Criteria
October 28, 2008
First Posted (Estimate)
October 31, 2008
Study Record Updates
Last Update Posted (Estimate)
February 29, 2016
Last Update Submitted That Met QC Criteria
January 29, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- CTD-2008-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.